These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Use of refortan in a complex therapy of intraoperative hemorrhage as a method of preservation of blood in pelvic operations in oncology patients].
    Author: Malanov VO, Kotenko OIe, Kalaputs VI, Fomina SO.
    Journal: Lik Sprava; 2001; (2):121-6. PubMed ID: 11519406.
    Abstract:
    Admitting the possibility of the surgical patient developing immunological incompatibility, danger of his catching an infectious disease, and a risk of technical errors we are obliged to review conceptions of transfusion of donor blood. A negative impact of hemotransfusions on the frequency of recurrencies and metastasizing in operations for malignant tumours has been amply demonstrated together with a rise in the incidence of postoperative pyo-inflammatory complications. Employment of blood-preserving methods in surgery permits avoiding transfusion of donor blood preparations. One of the main methods for blood preservation is pre- and intraoperative hemodilution involving the use of synthetic colloidal solutions. It has been shown in our studies that employment of refortan (hydroxyethyl starch--HES 200/0.5-6%) in a complex of preoperative infusion therapy permits dealing with hypovolemic disturbances effectively, cutting down preoperative preparation time. Intraoperative use of refortan obviates the need for transfusion of donor blood preparation in hemorrhage up to 20% of CBV. In a dose of 8-10 mg/kg, refortan prevents development of profuse hemorrhage-associated critical states.
    [Abstract] [Full Text] [Related] [New Search]